PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Therapies targeting programmed death 1-(PD-1) or its ligand (PD-L1), promoting antitumor T-cell activity have been successfully introduced into clinical practice. Clinical response correlates with PD-L1 expression by tumor cells or immune cells within the tumor microenvironment. The PD-L1/PD-1 axis and tumor microenvironment has been rarely studied in high-grade sarcomas of soft tissue (hSTS), a group of rare, genetically heterogenous and clinically aggressive tumors. We examined PD-L1 protein and CD274/PD-L1 gene copy number variations in 128 primary resected, therapy-naive hSTS using immunohistochemistry and fluorescence-in-situ hybridization. Frequency of tumoral PD-L1 expression varied widely in different disease subentities, with highest rates of positivity (40%) seen in undifferentiated pleomorphic sarcomas (UPS) and rare positivity detected in synovial sarcomas (6%). Amplification of the CD274/PD-L1 gene occurred in 14% of UPS and was rare in other subtypes. PD-L1 protein expression was significantly more frequent in CD274/PD-L1 amplified cases (p = 0.015). The subgroup of UPS was further characterized regarding the interaction between PD-L1 and the immunologic tumor microenvironment. High density of CD3+ and CD8+ tumor infiltrating lymphocytes (TILs) was significantly correlated with the presence of PD-L1 expression and seen more frequently in tumors with lower TNM stage (p = 0.024). Both, PD-L1 expression and high density lymphocytic infiltration were independent prognostic factors for a favorable overall (p = 0.001, HR 6.105 (2.041–8.258)), disease-specific (p = 0.003, HR 10.536 (2.186–50.774)) and disease-free survival (p = 0.020, HR 3.317 (1.209–9.106); values for CD8) in this particular subgroup of hSTS, whereas PD-L1 expression in TILs or CD274/PD-L1 gene amplification were not associated with outcome. These findings represent novel insights into the immune landscape of soft tissue sarcomas, in particular UPS and strengthen the rationale for immunotherapy, including targeting the PD-1/PD-L1 axis in these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 3×
“© 2018 Taylor & Francis Group, LLC presented on MHC-molecules leading to TC killing mediated particularly by CD8C effector T-cells.8,9,21 Based on the presence or absence of T-cells, the tumor microenvironment (TME) is classified as T-cell inflamed or non T-cell inflamed.6,8 In T-cell inflamed TME, presence of CD8C T-…”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 3×
“© 2018 Taylor & Francis Group, LLC presented on MHC-molecules leading to TC killing mediated particularly by CD8C effector T-cells.8,9,21 Based on the presence or absence of T-cells, the tumor microenvironment (TME) is classified as T-cell inflamed or non T-cell inflamed.6,8 In T-cell inflamed TME, presence of CD8C T-…”
BackgroundPD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · cited 1×
“In addition, we used the PD-L1 antibody clone SP263 for immunohistochemistry, which has been recommended as companion diagnostic in previous studies targeting PD-1/PD-L1 axis.(7,39,40) To avoid possible confounding effects of preoperative treatment on tumor immunology and TME, we included exclusively primary resected,…”
MethodTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 1×
“group of patients, especially those with undifferentiated pleomorphic sarcomas showed partial response.(17)”
BackgroundPD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787
Cited by
Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Cervantes-Villagrana, R. D., Albores-García, D., Cervantes-Villagrana, A. R., & García-Acevez, S. J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0205-z · Cited by 290
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
“linked danger signaling especially in the context of resistance to immunotherapy.(353,354)”
BackgroundKeung, E. Z., Burgess, M., Salazar, R., Parra, E. R., Rodrigues-Canales, J., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Attia, S., Riedel, R. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1824 · Cited by 215
Somaiah, N., Conley, A. P., Parra, E. R., Lin, H., Amini, B., Solis Soto, L., Salazar, R., Barreto, C., Chen, H., Gite, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00392-8 · Cited by 159
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials
Zhu, M. M. T., Shenasa, E., & Nielsen, T. O. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102115 · Cited by 75
Metadata
- Authors
- Boxberg, M., Steiger, K., Lenze, U., Rechl, H., von Eisenhart-Rothe, R., Wörtler, K., Weichert, W., Langer, R., & Specht, K.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-11-20
- Volume
- 7
- Issue
- 3
- Pages
- e1389366
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2765919158
- Cited by
- 87
- References
- 7
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy. https://app.cochat.ai/papers/10.1080/2162402x.2017.1389366
- The paper
- Boxberg, M., Steiger, K., Lenze, U., Rechl, H., von Eisenhart-Rothe, R., Wörtler, K., Weichert, W., Langer, R., & Specht, K. (2018). PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1389366
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.